These findings underscore the critical role of the ATF4-TRIB3 signaling axis in impairing efferocytosis in atherosclerosis and other dyslipidemic conditions, suggesting that therapeutics targeting this pathway could promote efferocytosis and accelerate the resolution of inflammation. The gene discussed is ATF4; the disease is atherosclerosis.